Evidence map›Paper›PMID 32462952›Full record

ArticleInternational journal of immunopathology and pharmacology

Amelioration of paraquat-induced pulmonary fibrosis in mice by regulating miR-140-5p expression with the fibrogenic inhibitor Xuebijing.

Min-Na Dong, Yun Xiao, Yun-Fei Li, Dong-Mei Wang, Ya-Ping Qu, Tian-Wen Fang, Hui Li, Ming-Wei Liu

Open access · goldAbstract read
In one paragraph

Article in International journal of immunopathology and pharmacology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Effect ofInternational journal of molecular and cellular medicine · 2023
    Article
  5. Article
  6. Article
  7. A Reasonable Evaluation ofJournal of analytical methods in chemistry · 2022
    Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Min-Na DongDepartment of Emergency, First Hospital Affiliated to Kunming Medical University, Kunming, China.
Yun XiaoIntensive Care Unit, The Third Affiliated Hospital of Kunming Medical University, Kunming, China.
Yun-Fei LiDepartment of Elderly Cardiovascular Diseases, First Hospital Affiliated to Kunming Medical University, Kunming, China.
Dong-Mei WangYunnan Green Field Biological Pharmaceutical Co., Ltd., Kunming, China.
Ya-Ping QuDepartment of Postgraduate, Kunming Medical University, Kunming, China.
Tian-Wen FangDepartment of Postgraduate, Kunming Medical University, Kunming, China.
Hui LiYunnan Green Field Biological Pharmaceutical Co., Ltd., Kunming, China.
Ming-Wei LiuDepartment of Emergency, First Hospital Affiliated to Kunming Medical University, Kunming, China.ORCID https://orcid.org/0000-0002-3728-2350
Kunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intravenous Xuebijing (XBJ) therapy suppresses paraquat (PQ)-induced pulmonary fibrosis. However, the mechanism underlying this suppression remains unknown. This work aimed to analyze the miR-140-5p-induced effects of XBJ injection on PQ-induced pulmonary fibrosis in mice. The mice were arbitrarily assigned to four groups. The model group was administered with PQ only. The PQ treatment group was administered with PQ and XBJ. The control group was administered with saline only. The control treatment group was administered with XBJ only. The miR-140-5p and miR-140-5p knockout animal models were overexpressed. The gene expression levels of miR-140-5p, transglutaminase-2 (TG2), β-catenin, Wnt-1, connective tissue growth factor (CTGF), mothers against decapentaplegic homolog (Smad), and transforming growth factor-β1 (TGF-β1) in the lungs were assayed with quantitative reverse transcription polymerase chain reaction (qRT-PCR) and Western blot analysis. The levels of TGF-β1, CTGF, and matrix metalloproteinase-9 (MMP-9) in the bronchoalveolar lavage fluid were assessed by enzyme-linked immunosorbent assay (ELISA). Hydroxyproline (Hyp) levels and pulmonary fibrosis were also scored. After 14 days of PQ induction of pulmonary fibrosis, AdCMV-miR-140-5p, and XBJ upregulated miR-140-5p expression; blocked the expressions of TG2, Wnt-1, and β-catenin; and decreased p-Smad2, p-Smad3, CTGF, MMP-9, and TGF-β1 expressions. In addition, Hyp and pulmonary fibrosis scores in XBJ-treated mice decreased. Histological results confirmed that PQ-induced pulmonary fibrosis in XBJ-treated lungs was attenuated. TG2 expression and the Wnt-1/β-catenin signaling pathway were suppressed by the elevated levels of miR-140-5p expression. This inhibition was pivotal in the protective effect of XBJ against PQ-induced pulmonary fibrosis. Thus, XBJ efficiently alleviated PQ-induced pulmonary fibrosis in mice.

Indexed as

A549 CellsAnimalsBronchoalveolar Lavage FluidDrugs, Chinese HerbalGene Expression RegulationHumansLungMaleMiceMice, Inbred C57BLMice, KnockoutMicroRNAsParaquatPulmonary FibrosisSignal TransductionDrugs, Chinese HerbalMicroRNAsMIRN140 microRNA, mouseParaquatXuebijingmatrix metalloproteinasemicemiR-140-5pparaquatpulmonary fibrosistransglutaminase-2Xuebijing

Identifiers

PMID32462952
PMCPMC7262989
OpenAlexW3028716120

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.